Work

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mds602

Authors: M.M. Mita, E. Poplin, C.D. Britten, W.D. Tap, E.H. Rubin, B.B. Scott, L. Berk, V.M. Rivera, J.W. Loewy, P. Dodion, F. Haluska, J. Sarantopoulos, A. Mita, A. Tolcher

Institutions: Rutgers Cancer Institute, University of California, Los Angeles, Memorial Sloan Kettering Cancer Center, ARIAD Pharmaceuticals (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Ariad Pharmaceuticals, Merck Sharp and Dohme

OpenAlex ID: W2117787192

FWCI: 2.447

Cites: 24

Cited by: 44

Related to: 10